Novo Holdings A/S Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001388325

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 26 positions · Total reported value $1.49B · Top-10 concentration 76.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 40.7% · 2 new · 8 cut · 1 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -12.9% · vs SPY -15.1% · Prev Value $1.72B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.6% · vs SPY -2.8% · Latest Value $1.49B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Novo Holdings A/S disclosed 26 equity positions with a combined reported value of $1.49B. The filing implies a focused portfolio: its ten largest positions account for 76.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were EWTX ($217.21M), ASML ($172.01M), BN ($162.80M). By sector, the heaviest allocations are Health Care 67.0%, Technology 17.7%. Versus the prior quarter, allocation shifted toward Technology (+2.8pp), Real Estate (+2.2pp) and away from Health Care (-2.3pp), Other (-2.9pp).

Versus the prior quarter, Novo Holdings A/S opened 2 new positions, trimmed 8 and fully exited 1, a turnover rate of 40.7% of positions. The portfolio's overlap with the prior quarter was 89% of names.

The largest new positions opened in Q3 2026 were SRRK ($22.23M), CTNM ($9.45M).

Of the 1 positions fully exited versus the prior quarter, the largest were CRNX ($49.39M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SRRK SCHOLAR ROCK HLDG CORP · $22.23M
  • CTNM CONTINEUM THERAPEUTICS INC · $9.45M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $49.39M

Insider Transactions (Form 4)

Latest Novo Holdings A/S buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-04 Conversion Hemab Therapeutics Holdings, Inc. 4,180,550 — SEC filing
2026-05-01 Buy Avalyn Pharma Inc. 555,555 $18.00 SEC filing
2026-05-01 Conversion Avalyn Pharma Inc. 3,327,734 — SEC filing

All insider transactions →

Fund Profile

Novo Holdings A/S files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 26 positions worth $1.49B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 26 positions · $1.49B reported value (Q3 2026)
  • Top 10 holdings = 76.1% of reported value
  • Largest position: EWTX (EDGEWISE THERAPEUTICS INC) at 14.6%
  • Average position size: $57.30M

Sector Tilt

  • Health Care 67.0%
  • Information Technology 17.7%
  • Real Estate 10.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 6 added, 8 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to Health Care (up 3.5% YoY) and Real Estate (up 2.25% YoY), while reducing Technology (down 0.42% YoY), suggesting a bullish stance on biotech/healthcare and real estate, with modest tech profit-taking. 2. Key moves: - Added: BN (Brookfield Corp, +27.7% shares), VRDN (Viridian Therapeutics, +128.3% shares). - Reduced: AVLN (Avalyn Pharmaceuticals, -11.2% shares), FDMT (4D Molecular Therapeutics, -7.7% shares). 3. Portfolio structure: Active, concentrated (top 10 = 75.99%), overweight Health Care (60.17%) vs. Technology (17.61%), with high risk (small/mid-cap biotech focus). 4. Per-holding one-liner: - EWTX: Edgewise Therapeutics (biotech, unverified). - ASML: ASML Holding (semiconductor equipment). - BN: Brookfield Corp (real estate/infrastructure). - COAG: Hemab Therapeutics (biotech, unverified). - AVLN: Avalyn Pharmaceuticals (biotech, unverified). - MIRM: Mirum Pharmaceuticals (biotech, unverified). - CRM: Salesforce (cloud software). - VRDN: Viridian Therapeutics (thyroid disease biotech, unverified). - ELVN: Enliven Therapeutics (biotech, unverified). - FDMT: 4D Molecular Therapeutics (gene therapy, unverified). 5. Style summary: Biotech/real estate overweight with selective tech additions, active management favoring high-growth therapeutics.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:27

Sector Allocation

Health Care 67.0%
Technology 17.7%
Real Estate 10.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.35M $217.21M 14.58%
14.58%
Hold
2 94.95K $172.01M 11.55%
11.55%
Hold
3 4.47M $162.80M 10.93%
10.93%
Add
4 4.18M $128.93M 8.65%
8.65%
Hold
5 3.45M $98.27M 6.60%
6.60%
Reduce
6 1.12M $96.17M 6.46%
6.46%
Hold
7 393.19K $90.26M 6.06%
6.06%
Hold
8 4.87M $78.92M 5.30%
5.30%
Add
9 1.00M $45.84M 3.08%
3.08%
Hold
10 3.00M $42.93M 2.88%
2.88%
Reduce
11 710.00K $40.40M 2.71%
2.71%
Reduce
12 797.00K $36.51M 2.45%
2.45%
Hold
13 1.18M $35.58M 2.39%
2.39%
Reduce
14 284.43K $32.46M 2.18%
2.18%
Add
15 1.02M $32.34M 2.17%
2.17%
Reduce
16 950.00K $30.79M 2.07%
2.07%
Reduce
17 257.33K $27.67M 1.86%
1.86%
Hold
18 652.11K $24.25M 1.63%
1.63%
Add
19 460.00K $22.23M 1.49%
1.49%
New
20 1.38M $22.17M 1.49%
1.49%
Add
21 2.09M $21.26M 1.43%
1.43%
Reduce
22 704.01K $9.45M 0.63%
0.63%
New
23 1.25M $9.24M 0.62%
0.62%
Add
24 2.25M $9.22M 0.62%
0.62%
Hold
25 110.39K $1.88M 0.13%
0.13%
Reduce
26 158.15K $903.02K 0.06%
0.06%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Low-confidence forecast This fund replaces about 23% of its Top-10 each quarter and backtests at F1 76% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 76% · recall 76% · F1 76% · avg rank error 1.9 · Top-10 turnover 23%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% BN · ASML · CRM · SPRO · LNZA · TSM · CORT · EWTX · CABO · PCVX ASML · BN · CRM · EPC · CORT · PCVX · CRNX · CABO · LNZA · FDMT
2024-Q2 50% 50% 50% ASML · BN · CRM · EPC · PCVX · CORT · CRNX · CABO · LNZA · FDMT VTI · BN · TEM · ASML · CRM · EWTX · CORT · PCVX · INSM · MIRM
2024-Q3 90% 90% 90% VTI · BN · TEM · ASML · CRM · EWTX · CORT · PCVX · MIRM · INSM VTI · TEM · BN · EWTX · CORT · ASML · CRM · PCVX · MIRM · VRDN
2024-Q4 80% 80% 80% VTI · TEM · BN · EWTX · CORT · ASML · CRM · PCVX · VRDN · MIRM VTI · BN · TEM · EWTX · ASML · CRM · RXRX · MIRM · PCVX · INSM
2025-Q1 80% 80% 80% VTI · BN · TEM · EWTX · ASML · CRM · RXRX · MIRM · PCVX · INSM VTI · BN · EWTX · ASML · CRM · MIRM · INSM · RXRX · BABA · CRNX
2025-Q2 100% 100% 100% VTI · EWTX · BN · ASML · CRM · MIRM · INSM · RXRX · BABA · CRNX VTI · BN · ASML · CRM · MIRM · EWTX · INSM · RXRX · CRNX · BABA
2025-Q3 70% 70% 70% VTI · BN · ASML · CRM · MIRM · EWTX · INSM · RXRX · CRNX · AVBP VTI · BN · ASML · MIRM · EWTX · CRM · MRUS · CRNX · VRDN · BABA
2025-Q4 70% 70% 70% VTI · BN · ASML · MIRM · EWTX · CRM · MRUS · CRNX · VRDN · BABA BN · EWTX · ASML · MIRM · CRM · CRNX · VRDN · MPLT · ZBIO · PHVS
2026-Q1 80% 80% 80% BN · EWTX · ASML · MIRM · CRM · CRNX · VRDN · MPLT · ZBIO · PHVS EWTX · BN · ASML · MIRM · MPLT · CRM · CRNX · ELVN · PCVX · PHVS
2026-Q2 70% 70% 70% EWTX · BN · MIRM · ASML · MPLT · CRM · CRNX · PCVX · ELVN · PHVS EWTX · ASML · COAG · BN · MPLT · MIRM · AVLN · CRM · AVBP · ELVN
2026-Q3 ★ 80% 80% 80% EWTX · ASML · COAG · BN · MPLT · MIRM · AVLN · CRM · AVBP · ELVN EWTX · ASML · BN · COAG · AVLN · MIRM · CRM · VRDN · ELVN · FDMT

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings8 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-10.25%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+6.77%vs benchmark
Barra annualised vol26.2%Model estimate
Realised vol29.0%Annualised in window
Weighted beta1.40Raw exposure
Factor / specific risk66% / 34%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16Novo Holdings A/SQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-10.25%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+6.77%Portfolio − benchmark
Arithmetic return sum-10.25%Difference vs compounded is the cross term
Weighted raw beta1.40Weighted holding betas
Realised volatility (annualised)29.01%Daily returns in window
Barra model volatility (annualised)26.16%Factor + specific
Factor share of variance66.1%Barra factors
Specific share of variance33.9%Stock residuals
Reported value$552.5M13F long US equity

2. Return attribution

The -10.25% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -1.13% -11.1%
Momentum & Growth 3 -0.42% -4.1%
Volatility & Tail Risk 7 -0.10% -1.0%
Industry 12 +0.43% 4.2%
Specific 1 -9.03% -88.0%
Return attribution (style + industry, %)-2.8-1.4+0.0+1.4+2.8Consumer Discretionary+0.34Leverage (Downside Vol)+0.37Momentum-0.47Non-linear Size+0.54Turnover+0.96Health Care+1.26Real Estate+1.27Residual Volatility-1.33Skewness-1.60Historical Volatility-2.03Kurtosis+2.07Information Technology-2.44Beta+2.45Mid Cap-2.57
Factor Type Exposure Factor return Contribution Share of |return|
Beta Style +0.55 +4.44% +2.45% 23.9%
Kurtosis Style +0.28 +7.51% +2.07% 20.2%
Real Estate Industry +0.29 +4.31% +1.27% 12.4%
Health Care Industry +0.18 +6.98% +1.26% 12.3%
Turnover Style -0.20 -4.80% +0.96% 9.3%
Non-linear Size Style +0.54 +1.01% +0.54% 5.3%
Leverage (Downside Vol) Style -0.22 -1.71% +0.37% 3.6%
Consumer Discretionary Industry +0.05 +6.71% +0.34% 3.3%
Size Style -0.05 -1.95% +0.10% 1.0%
Short-term Reversal Style +0.09 +0.87% +0.08% 0.8%
Liquidity Style +0.15 +0.36% +0.06% 0.5%
Amihud Illiquidity Style +0.50 -0.45% -0.22% -2.2%
Momentum Style +0.12 -4.00% -0.47% -4.6%
Residual Volatility Style -0.40 +3.29% -1.33% -12.9%
Skewness Style +0.36 -4.39% -1.60% -15.6%
Historical Volatility Style +0.15 -14.00% -2.03% -19.8%
Information Technology Industry +0.47 -5.13% -2.44% -23.8%
Mid Cap Style +1.33 -1.94% -2.57% -25.0%
Specific Specific — — -9.03% -88.0%

3. Risk attribution

Annualised volatility is 26.16%; factor risk explains 66.1% of variance and specific risk 33.9%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-36.6-18.3+0.0+18.3+36.6Skewness-1.54Amihud Illiquidity-0.85Turnover-0.37Residual Volatility+0.26Size+0.34Historical Volatility+0.88Consumer Discretionary+1.36Leverage (Downside Vol)+1.47Health Care+5.21Mid Cap+11.49Real Estate+13.56Beta+16.36Information Technology+17.88Specific+33.92
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 33.9% +8.87% 8.9%
Information Technology Industry +0.47 17.9% +4.68% 4.7%
Beta Style +0.55 16.4% +4.28% 4.3%
Real Estate Industry +0.29 13.6% +3.55% 3.5%
Mid Cap Style +1.33 11.5% +3.01% 3.0%
Health Care Industry +0.18 5.2% +1.36% 1.4%
Leverage (Downside Vol) Style -0.22 1.5% +0.38% 0.4%
Consumer Discretionary Industry +0.05 1.4% +0.35% 0.3%
Historical Volatility Style +0.15 0.9% +0.23% 0.2%
Size Style -0.05 0.3% +0.09% 0.1%
Residual Volatility Style -0.40 0.3% +0.07% 0.1%
Momentum Style +0.12 0.2% +0.07% 0.1%
Turnover Style -0.20 -0.4% -0.10% -0.1%
Amihud Illiquidity Style +0.50 -0.8% -0.22% -0.2%
Skewness Style +0.36 -1.5% -0.40% -0.4%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.71.62.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.05 +2.10 -2.15
Non-linear Size +0.54 +1.68 -1.14
Mid Cap +1.32 +0.13 +1.20
Beta +0.55 +1.29 -0.74
Momentum +0.12 +0.72 -0.60
Short-term Reversal +0.09 -0.64 +0.74
Residual Volatility -0.40 -0.40 -0.00
Historical Volatility +0.14 +0.86 -0.71
Liquidity +0.15 +0.11 +0.04
Amihud Illiquidity +0.50 +1.16 -0.66
Turnover -0.20 +0.21 -0.41
Growth -0.02 +0.58 -0.60
Leverage (Downside Vol) -0.22 +0.14 -0.36
Skewness +0.36 +0.24 +0.12
Kurtosis +0.28 +0.21 +0.06
Max Drawdown +0.02 -0.08 +0.11

5. Industry allocation & Brinson

Industry allocation (weight, %)-7.414.736.858.981.0Communication ServicesUtilitiesConsumer StaplesIndustrialsConsumer DiscretionaryHealth CareReal EstateInformation TechnologyPortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 47.5% 73.6% -16.87% -22.33% +1.36% +4.02% -1.43% +8.43%
Real Estate 29.5% 0.0% +10.78% +0.00% +5.05% +0.00% +3.18% +3.18%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Consumer Discretionary 5.0% 8.8% -15.73% +3.76% -0.80% -1.72% +0.74% -1.12%
Health Care 18.0% 1.7% -23.96% +8.29% +4.15% -0.56% -5.26% -4.47%
Total +6.78% +1.48% -2.50% +5.75%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
ASML ASML HLDG NV Information Technology 31.14% -22.35% -6.96% Hold
BN BROOKFIELD CORP Real Estate 29.47% +10.78% +3.18% Add
CRM SALESFORCE INC Information Technology 16.34% -6.42% -1.05% Hold
AVBP ARRIVENT BIOPHARMA INC Health Care 6.44% -61.82% -3.98% Reduce
INSM INSMED INC Health Care 5.88% +7.66% +0.45% Add
BABA ALIBABA GROUP HLDG LTD Consumer Discretionary 5.01% -15.73% -0.79% Hold
SRRK SCHOLAR ROCK HLDG CORP Health Care 4.02% -7.82% -0.32% New
CTNM CONTINEUM THERAPEUTICS INC Health Care 1.71% -27.94% -0.48% New
Contribution rank Symbol Sector Weight Return Contribution
1 BN Real Estate 29.47% +10.78% +3.18%
2 INSM Health Care 5.88% +7.66% +0.45%
3 SRRK Health Care 4.02% -7.82% -0.32%
4 CTNM Health Care 1.71% -27.94% -0.48%
5 BABA Consumer Discretionary 5.01% -15.73% -0.79%
6 CRM Information Technology 16.34% -6.42% -1.05%
7 AVBP Health Care 6.44% -61.82% -3.98%
8 ASML Information Technology 31.14% -22.35% -6.96%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -10.25%, versus -17.01% for the QQQ synthetic benchmark — an excess of +6.77%.
  2. Return attribution: the largest positive style/industry contributions came from Beta +2.45%, Kurtosis +2.07%, Real Estate +1.27%; the largest drags came from Mid Cap -2.57%, Information Technology -2.44%, Historical Volatility -2.03%. Specific (stock-level) return contributed -9.03%.
  3. Risk attribution: Barra model volatility is 26.16% annualised; factor risk explains 66% of variance and specific risk 34%. The largest factor risk sources are Information Technology 17.9%, Beta 16.4%, Real Estate 13.6%.
  4. Style tilt: size -0.05, momentum +0.12, volatility +0.14, liquidity +0.15; the weighted raw beta is 1.40. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Real Estate (+29.5 pp), the largest underweight is Information Technology (-26.2 pp). Allocation contributed +6.78%, selection +1.48% and interaction -2.50%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Novo Holdings A/S buy in 2026-Q3?

In its 2026-Q3 13F filing, Novo Holdings A/S reported 26 equity positions worth $1.49B in aggregate; its largest disclosed positions were EWTX ($217.21M), ASML ($172.01M), BN ($162.80M).

How large is Novo Holdings A/S's portfolio?

Novo Holdings A/S reported $1.49B of long equity holdings across 26 positions as of 2026-Q3. Top-10 holdings account for 76.1% of reported value.

What is Novo Holdings A/S's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/novo-holdings-a-s/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →